期刊
INTERNAL MEDICINE JOURNAL
卷 47, 期 1, 页码 112-115出版社
WILEY-BLACKWELL
DOI: 10.1111/imj.13308
关键词
idiopathic inflammatory myopathy; intravenous immunoglobulin; dermatomyositis; polymyositis; inclusion body myositis
In South Australia, between 2000 and 2014, 57 patients with idiopathic inflammatory myositis (IIM) were treated with intravenous immunoglobulin (IVIg). We reviewed disease characteristics to determine predictors of response to therapy and IVIg dosing and duration to identify opportunities to rationalise IVIg use. Patients with dermatomyositis/polymyositis had a response rate of 77% and were more likely than inclusion body myositis to respond to therapy. Consideration should be given to the use of the lowest possible dose of IVIg and to the undertaking of trials of cessation of IVIg in patients with stable IIM.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据